What happened

Spyre Therapeutics, Inc. (NASDAQ: SYRE) Chief Legal Officer and Corporate Secretary Heidy King-Jones sold 28,933 shares on 2026-10-01.

The Form 4 shows five sale blocks at weighted-average prices from $89.24 to $93.46 per share, totaling about $2.63 million. It also shows a separate 28,933-share option exercise at $14.5 per share, and the filing says full price-by-price details are available on request.

The filing says the trades were made under a Rule 10b5-1 trading plan adopted on April 16, 2026. The form was filed on 2026-10-02.

After the reported transactions, King-Jones held 2,845 shares and 482,478 stock options. The option represents the right to purchase 539,810 shares of common stock, adjusted for the company's 1-for-25 reverse stock split on September 8, 2023.

One quarter vested on September 1, 2024, and the remaining three quarters vest monthly over the following three years. The option expires on September 1, 2033, subject to continued employment with the issuer.

Explain the financial terms

A fiscal quarter is a three-month period in the company's reporting year.

A Form 4 is the SEC report an officer, director or 10% owner files within two business days of buying or selling the company's stock.

A Rule 10b5-1 plan is a trading plan an insider sets up in advance, while not holding inside information, that schedules later trades.

Why it matters

OptimistFi's case is that Spyre is a high-risk clinical-stage option on long-acting antibody and antibody-combination drugs. This filing mainly updates insider exposure. OptimistFi's calculation shows the 28,933 shares were about 91.0% of the holding before the trade.

That makes the sale a large reduction in direct ownership. The $2.63 million figure covers the five sale blocks only, not the separate option exercise at $14.5 per share.

The Rule 10b5-1 plan and the 2,845 shares still held afterward keep the filing from reading as a fresh operating signal. King-Jones also still held 482,478 stock options after the transactions.

The filing separates the option exercise from the sale blocks, so the $2.63 million figure covers only the sales.

Explain the financial terms

A Rule 10b5-1 plan is a trading plan an insider sets up in advance, while not holding inside information, that schedules later trades.

What's next

King-Jones still held 2,845 shares and 482,478 stock options after the reported transactions. That leaves the filing's disclosed stake as the baseline for any later sales made under the named plan.

The plan adopted on April 16, 2026 and the option's monthly vesting schedule set the filing's timing context for the remaining position.

Sources checked automatically Oct 3, 2026 · Human review: none
Thesis impactSYRE: no published thesis yet.